| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| QSAM Biosciences, Inc. | Director | Common Stock | 2.88M | $8.65M | $3.00 | Dec 6, 2021 | Direct |
| QSAM Biosciences, Inc. | Director | Options to buy common | 55K | Aug 24, 2021 | Direct | ||
| SAB Biotherapeutics, Inc. | Director | Stock Option (right to buy) | 9.31K | Jul 15, 2024 | Direct | ||
| QSAM Biosciences, Inc. | Director | Series E-1 Preferred Shares | 0 | Feb 15, 2021 | Direct | ||
| QSAM Biosciences, Inc. | Director | Series E-1 Preferred Stock | 0 | Dec 6, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | Jul 15, 2024 | 2 | $0 | 4 | Jul 17, 2024 | Director |
| SABS | SAB Biotherapeutics, Inc. | Dec 7, 2022 | 2 | $50K | 4 | Dec 9, 2022 | Director |
| QSAM | QSAM Biosciences, Inc. | Dec 31, 2021 | 4 | $0 | 5 | Feb 15, 2022 | Director |
| SABS | SAB Biotherapeutics, Inc. | Oct 22, 2021 | 7 | $0 | 4 | Oct 26, 2021 | Director |
| SABS | Big Cypress Acquisition Corp. | Oct 22, 2021 | 0 | $0 | 3 | Oct 22, 2021 | Director |